Development of a nanomedicine-loaded hydrogel for sustained delivery of an angiogenic growth factor to the ischaemic myocardium
The 5-year mortality rate for heart failure borders on 50%. The main cause is an ischaemic cardiac event where blood supply to the tissue is lost and cell death occurs. Over time, this damage spreads and the heart is no longer able to pump efficiently. Increasing vascularisation of the affected area has been shown to reduce patient symptoms. The growth factors required to do this have short half-lives making development of an efficacious therapy difficult. Herein, the angiogenic growth factor Vascular Endothelial Growth Factor (VEGF) is complexed electrostatically with star-shaped or linear polyglutamic acid (PGA) polypeptides. Optimised PGA-VEGF nanomedicines provide VEGF encapsulation of > 99% and facilitate sustained release of VEGF for up to 28 days in vitro. The star-PGA-VEGF nanomedicines are loaded into a percutaneous delivery compliant hyaluronic acid hydrogel. Sustained release of VEGF from the composite nano-in-gel system is evident for up to 35 days and the released VEGF has comparable bioactivity to free, fresh VEGF when tested on both Matrigel® and scratch assays. The final star-PGA-VEGF nanomedicine-loaded hydrogel is biocompatible and provides sustained release of bioactive VEGF. Therefore, we report the development of novel, self-assembling PGA-VEGF nanomedicines and their incorporation into a hyaluronic acid hydrogel that is compatible with medical devices to enable minimally invasive delivery to the heart. The final star-PGA-VEGF nanomedicine-loaded hydrogel is biocompatible and provides sustained release of bioactive VEGF. This formulation provides the basis for optimal spatiotemporal delivery of an angiogenic growth factor to the ischaemic myocardium.
KeywordsStar polypeptide Nanoparticle Angiogenesis Growth factor Ischaemia
The authors acknowledge the support of Brenton Cavanagh for assistance with imaging and Matrigel® analysis.
Financial support for this project was provided by Science Foundation Ireland (SFI) under an Investigator Award grant number 13/IA/1840 and the AMCARE consortium, a European Union’s Seventh Framework Programme (FP7/2007-2013) under grant agreement number 604531.
- 1.Pittman RN. The circulatory system and oxygen transport. In: Regulation of tissue oxygenation. Morgan & Claypool Life Sciences: San Rafael; 2011.Google Scholar
- 2.Alberts B, Johnson A, Lewis J, Raff M, Roberts K, Walter P. Blood vessels and endothelial cells. In: Molecular biology of the cell. 4th ed. New York: Garland Science; 2002.Google Scholar
- 8.Adair TH, Montani J-P. Angiogenesis. Morgan & Claypool Life Sciences; 2010.Google Scholar
- 28.Dolan EB, Kovarova L, O’Neill H, Pravda M, Sulakova R, Scigalkova I, et al. Advanced Material Cath eter (AMCath), a minimally invasive endocardial catheter for the delivery of fast-gelling covalently cross-linked hyaluronic acid hydrogels. J Biomater Appl. 2018;33(5):681–92.PubMedCrossRefGoogle Scholar
- 34.Quinlan E, López-Noriega A, Thompson EM, Hibbitts A, Cryan SA, O’Brien FJ. Controlled release of vascular endothelial growth factor from spray-dried alginate microparticles in collagen-hydroxyapatite scaffolds for promoting vascularization and bone repair. J Tissue Eng Regen Med. 2017;11(4):1097–109.PubMedCrossRefPubMedCentralGoogle Scholar
- 40.Rui J, Dadsetan M, Runge MB, Spinner RJ, Yaszemski MJ, Windebank AJ, et al. Controlled release of vascular endothelial growth factor using poly-lactic-co-glycolic acid microspheres: in vitro characterization and application in polycaprolactone fumarate nerve conduits. Acta Biomater. 2012;8(2):511–8.PubMedCrossRefPubMedCentralGoogle Scholar
- 41.Mortensen A, Aguilar F, Crebelli R, Di Domenico A, Dusemund B, Frutos MJ, et al. Re-evaluation of glutamic acid (E 620), sodium glutamate (E 621), potassium glutamate (E 622), calcium glutamate (E 623), ammonium glutamate (E 624) and magnesium glutamate (E 625) as food additives. EFSA J. 2017;15(7).Google Scholar
- 46.Mann DL, Lee RJ, Coats AJS, Neagoe G, Dragomir D, Pusineri E, et al. One-year follow-up results from AUGMENT-HF: a multicentre randomized controlled clinical trial of the efficacy of left ventricular augmentation with Algisyl in the treatment of heart failure. Eur J Heart Fail. 2016;18(3):314–25.PubMedCrossRefPubMedCentralGoogle Scholar